Evidence map›Paper›PMID 37961215›Full record

ArticleResearch square2023

Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R〿2-targeting CAR T cells: an interim analysis.

Leo Wang, Angela Taravella Oill, M Blanchard, Melody Wu, Jonathan Hibbard, Sean Sepulveda, Lance Peter, Julie Kilpatrick, Margarita Munoz, Tracey Stiller and 25 more

Registry-linked trialOpen access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04510051 (Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain Tumors), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04510051 phase1recruitingnot on this map

Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Children With Recurrent/Refractory Malignant Brain Tumors

TypeinterventionalSponsorCity of Hope Medical CenterRan2020 to 2027Enrolled18ConditionsMalignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain NeoplasmArmsCyclophosphamide, Fludarabine, IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 6 institutions in 1 country.

Leo WangCity of Hope.ORCID 0000-0002-2945-9005
Angela Taravella OillTranslational Genomics Research Institute.
M BlanchardCity Of Hope National Medical Center.
Melody WuCity of Hope National Medical Center.
Jonathan HibbardBeckman Research Institute, City of Hope National Medical Center.
Sean SepulvedaCity of Hope National Medical Center.
Lance PeterTranslational Genomics Research Institute.
Julie KilpatrickCity of Hope National Medical Center.
Margarita MunozCity of Hope National Medical Center.
Tracey StillerCity of Hope.
Noah ShulkinCity of Hope National Medical Center.
Jamie WagnerCity of Hope.
Ally DolatabadiCity of Hope National Medical Center.
Monica NisisCity of Hope National Medical Center.
Jennifer ShepphirdCity of Hope National Medical Center.
Gabriela SanchezCity of Hope National Medical Center.
Chetan LingarajuCity of Hope National Medical Center.
Mishika ManchandaCity of Hope National Medical Center.
Heini NatriThe Translational Genomics Research Institute.
Léonce KouakanouCity of Hope National Medical Center.
Grace SunCity of Hope National Medical Center.
Cheryl Oliver-CervantesCity of Hope National Medical Center.
Joseph GeorgesCity of Hope National Medical Center.
Maryam AftabizadehCity of Hope National Medical Center.
Stephen FormanCity Of Hope National Medical Center.ORCID 0000-0002-2803-4152
Saul PricemanCity of Hope.ORCID 0000-0002-8136-2112
Julie ResslerCity of Hope National Medical Center.
Leonidas Arvanitis7Department of Pathology, City of Hope, Duarte, CA, USA.
Jennifer CotterChildren's Hospital of Los Angeles.
Massimo D'ApuzzoCity of Hope Comprehensive Cancer Center.ORCID 0000-0001-8146-0997
Benita TamraziUniversity of Southern California.
Behnam BadieCity of Hope.
Tom DavidsonChildren's Hospital Los Angeles.ORCID 0000-0002-1655-3860
Nicholas BanovichTranslational Genomics Research Institute.
Christine BrownCity Of Hope National Medical Center.ORCID 0000-0003-4915-8207
City Of Hope National Medical Center · USTranslational Genomics Research Institute · USCity of Hope · USChildren's Hospital of Los Angeles · USUniversity of Southern California · USWeatherford College · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Role of Receptor for Advanced Glycation End Product (RAGE) Pathway in Brain TumorsR01CA155769 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BADIE, BEHNAM · 2011 to 2021
$3.8M
Phase 1 Study of Cellular Immunotherapy Using Optimized IL13Ra2 Specific CAR T cells for the Treatment of Malignant Glioma R01FD005129 · FDA · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BADIE, BEHNAM, BROWN, CHRISTINE · 2015 to 2017
$600k
FDA HHS R01 FD005129NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA155769
6 · The paper itself

Abstract

Outcomes for pediatric brain tumor patients remain poor, and there is optimism that chimeric antigen receptor (CAR) T cell therapy can improve prognosis. Here, we present interim results from the first six pediatric patients treated on an ongoing phase I clinical trial (NCT04510051) of IL13BBζ-CAR T cells delivered weekly into the lateral cerebral ventricles, identifying clonal expansion of endogenous CAR-negative CD8

Identifiers

PMID37961215
PMCPMC10635314
OpenAlexW4387881101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.